What were the results of the Phase 2 study of VX-770?
A Phase 2 clinical trial of the Vertex compound VX-770 showed that the compound, when taken orally, improved several key indicators of cystic fibrosis, including lung function, nasal potential difference measures and sweat chloride levels. This suggests that VX-770 acts to improve function of the malformed CFTR protein. This was a small, short-term study with 39 cystic fibrosis patients over a 14-day or 28-day period. Additional trials are needed, but the early results are encouraging.
